| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Alvarez, F Bronfman, C A Pérez, M Vicente, J Garrido, N C Inestros. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. Neuroscience letters. vol 201. issue 1. 1996-10-16. PMID:8830310. |
acetylcholinesterase (ache) colocalizes with amyloid-beta peptide (a beta) deposits present in the brain of alzheimer's patients. |
1996-10-16 |
2023-08-12 |
Not clear |
| T Irie, K Fukushi, H Namba, M Iyo, H Tamagami, S Nagatsuka, N Ikot. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 37. issue 4. 1996-08-26. PMID:8691261. |
brain acetylcholinesterase activity: validation of a pet tracer in a rat model of alzheimer's disease. |
1996-08-26 |
2023-08-12 |
rat |
| G M Bores, F P Huger, W Petko, A E Mutlib, F Camacho, D K Rush, D E Selk, V Wolf, R W Kosley, L Davis, H M Varga. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. The Journal of pharmacology and experimental therapeutics. vol 277. issue 2. 1996-06-27. PMID:8627552. |
pharmacological evaluation of novel alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. |
1996-06-27 |
2023-08-12 |
rat |
| G M Bores, F P Huger, W Petko, A E Mutlib, F Camacho, D K Rush, D E Selk, V Wolf, R W Kosley, L Davis, H M Varga. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. The Journal of pharmacology and experimental therapeutics. vol 277. issue 2. 1996-06-27. PMID:8627552. |
acetylcholinesterase (ache) inhibitors from several chemical classes have been tested for the symptomatic treatment of alzheimer's disease; however, the therapeutic success of these compounds has been limited. |
1996-06-27 |
2023-08-12 |
rat |
| J J Sramek, R Anand, T S Wardle, P Irwin, R D Hartman, N R Cutle. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life sciences. vol 58. issue 15. 1996-06-03. PMID:8614273. |
sdz ena 713 (ena 713) is an acetylcholinesterase inhibitor being developed as a potential treatment for alzheimer's disease (ad). |
1996-06-03 |
2023-08-12 |
Not clear |
| N C Inestrosa, A Alvarez, C A Pérez, R D Moreno, M Vicente, C Linker, O I Casanueva, C Soto, J Garrid. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. vol 16. issue 4. 1996-05-28. PMID:8608006. |
acetylcholinesterase accelerates assembly of amyloid-beta-peptides into alzheimer's fibrils: possible role of the peripheral site of the enzyme. |
1996-05-28 |
2023-08-12 |
mouse |
| N C Inestrosa, A Alvarez, C A Pérez, R D Moreno, M Vicente, C Linker, O I Casanueva, C Soto, J Garrid. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. vol 16. issue 4. 1996-05-28. PMID:8608006. |
acetylcholinesterase (ache), an important component of cholinergic synapses, colocalizes with amyloid-beta peptide (a beta) deposits of alzheimer's brain. |
1996-05-28 |
2023-08-12 |
mouse |
| Q X Zhi, F H Yi, C T X. Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuroreport. vol 6. issue 16. 1996-04-18. PMID:8595207. |
huperzine a, a novel, potent, reversible, and selective acetylcholinesterase (ache) inhibitor has been expected to be superior to other ache inhibitors now for the treatment of memory deficits in patients with alzheimer's disease. |
1996-04-18 |
2023-08-12 |
rat |
| J Dow, B D Dulery, J M Hornsperger, G F Di Francesco, P Keshary, K D Haegel. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery. Arzneimittel-Forschung. vol 45. issue 12. 1996-04-11. PMID:8595078. |
mdl 73,745 (2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone, cas 132236(18-1) is a novel tight-binding inhibitor of acetylcholinesterase (ache), which is in development as a potential therapeutic compound in the symptomatic treatment of alzheimer's disease. |
1996-04-11 |
2023-08-12 |
dog |
| W Tong, E R Collantes, Y Chen, W J Wels. A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors. Journal of medicinal chemistry. vol 39. issue 2. 1996-02-28. PMID:8558505. |
these compounds have been found to inhibit the metabolic breakdown of the neurotransmitter acetylcholine (ach) by the enzyme acetylcholinesterase (ache) and hence alleviate memory deficits in patients with alzheimer's disease by potentiating cholinergic transmission. |
1996-02-28 |
2023-08-12 |
human |
| C Geula, M M Mesula. Cholinesterases and the pathology of Alzheimer disease. Alzheimer disease and associated disorders. vol 9 Suppl 2. 1996-02-07. PMID:8534419. |
alzheimer disease (ad) is accompanied by a marked loss of acetylcholinesterase (ache) activity associated with cortical cholinergic axons and cholinoceptive neurons. |
1996-02-07 |
2023-08-12 |
Not clear |
| G Pacheco, R Palacios-Esquivel, D E Mos. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. The Journal of pharmacology and experimental therapeutics. vol 274. issue 2. 1995-09-08. PMID:7636741. |
cholinesterase inhibitors proposed for treating dementia in alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. |
1995-09-08 |
2023-08-12 |
human |
| J K Woo, M S Lant. Alzheimer's disease: how to give and monitor tacrine therapy. Geriatrics. vol 50. issue 5. 1995-06-08. PMID:7737527. |
up to one-third of patients with mild to moderate alzheimer's disease may show improvement in cognitive function with tacrine, a centrally-acting, noncompetitive inhibitor of acetylcholinesterase. |
1995-06-08 |
2023-08-12 |
Not clear |
| M R Emmerling, V E Gregor, R D Schwarz, J D Scholten, M J Callahan, C Lee, C J Moore, C Raby, W J Lipinski, R E Davi. PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Molecular neurobiology. vol 9. issue 1-3. 1995-04-18. PMID:7888109. |
inhibition of brain acetylcholinesterase (ache) can provide relief from the cognitive loss associated with alzheimer's disease (ad). |
1995-04-18 |
2023-08-12 |
rat |
| C H Konings, P Scheltens, M A Kuiper, C Mulder, J Calliauw, E C Wolter. Cerebrospinal fluid acetylcholinesterase homospecific activity in patients with "probable Alzheimer's disease". Biological psychiatry. vol 36. issue 10. 1995-04-13. PMID:7880942. |
cerebrospinal fluid acetylcholinesterase homospecific activity in patients with "probable alzheimer's disease". |
1995-04-13 |
2023-08-12 |
Not clear |
| M Schordere. Alzheimer's disease: fundamental and therapeutic aspects. Experientia. vol 51. issue 2. 1995-03-31. PMID:7875258. |
several compounds are being tested in attempts to prevent and/or cure alzheimer's disease, including tacrine, which has very modest efficacy in a sub-group of patients, and new acetylcholinesterase inhibitors. |
1995-03-31 |
2023-08-12 |
mouse |
| L Minthon, L Edvinsson, L Gustafso. Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease. Dementia (Basel, Switzerland). vol 5. issue 6. 1995-03-29. PMID:7866482. |
biochemical and histochemical studies have demonstrated a widespread deficit in the activity of acetylcholinesterase (ache) in the brains of patients with alzheimer's disease (dat). |
1995-03-29 |
2023-08-12 |
Not clear |
| S Iijima, N H Greig, P Garofalo, E L Spangler, B Heller, A Brossi, D K Ingra. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology. vol 112. issue 4. 1995-03-29. PMID:7871051. |
we have assessed the potential clinical value of phenserine for cholinomimetic therapy of cognitive impairments associated with aging and alzheimer's disease by evaluating its duration of in vivo activity against rat plasma acetylcholinesterase (ache) and its effect on attenuating a scopolamine-induced impairment in learning performance of young rats in a shock-motivated 14-unit t-maze. |
1995-03-29 |
2023-08-12 |
rat |
| Z X She. Acetylcholinesterase provides deeper insights into Alzheimer's disease. Medical hypotheses. vol 43. issue 1. 1994-12-07. PMID:7968717. |
acetylcholinesterase provides deeper insights into alzheimer's disease. |
1994-12-07 |
2023-08-12 |
Not clear |
| C Geula, B D Greenberg, M M Mesula. Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid. Brain research. vol 644. issue 2. 1994-09-08. PMID:8050043. |
previous histochemical observations in our laboratory have demonstrated the presence of butyrylcholinesterase and an enzymatically altered form of acetylcholinesterase activity in the plaques, tangles and amyloid-containing vessels of alzheimer's disease. |
1994-09-08 |
2023-08-12 |
Not clear |